

# **Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020**

<https://marketpublishers.com/r/GDA5D9EABACEN.html>

Date: January 2017

Pages: 112

Price: US\$ 1,200.00 (Single User License)

ID: GDA5D9EABACEN

## **Abstracts**

With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020” provides an in-depth analysis of global biosimilars market focusing on key segments detailing approved and upcoming biosimilar products. Market outlook for aforementioned biosimilar classes has been provided for the period 2017-20.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-

### Market Segmentation by Classes

Insulin

Erythropoietin (EPO)

Human Growth Hormone (HGH)

Granulocyte- Colony Stimulating Factor (G-CSF)

Monoclonal Antibody (mAb)

Interferon (IFN)

### Market Segmentation by Geography

Developed Markets – Europe and the US

Emerging Markets – China & India

### Key Vendors

Sandoz

Hospira

TEVA

Celltrion

Biocad

Dong-A Pharmaceutical Co., Ltd.

Stada

## Contents

### 1. EXECUTIVE SUMMARY

### 2. RESEARCH METHODOLOGY

### 3. INTRODUCTION

### 4. GLOBAL BIOLOGICS MARKET

#### 4.1 OVERVIEW

##### 4.1.1 Classification of Biologics

#### 4.2 GLOBAL BIOLOGICS MARKET ANALYSIS

##### 1.1.1 Market Sizing (Actual & Forecasted)

### 5. GLOBAL BIOSIMILARS MARKET

#### 5.1 OVERVIEW

#### 5.2 MARKET ANALYSIS

##### 5.2.1 Market Sizing (Actual & Forecasted)

##### 2.1.1 Market Share by Region (Actual & Forecasted)

##### 3.1.1 Market Share by Application (Actual & Forecasted)

##### 4.1.1 Market by Product Pipeline

### 6. GLOBAL BIOSIMILARS MARKET SEGMENTATION

#### 6.1 ERYTHROPOIETIN (EPO)

##### 6.1.1 Overview

##### 6.1.2 Market Analysis

#### 6.2 INSULIN

##### 6.2.1 Overview

##### 6.2.2 Market Analysis

#### 6.3 HUMAN GROWTH HORMONE (HGH)

##### 6.3.1 Overview

##### 6.3.2 Market Analysis

#### 6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF)

##### 6.4.1 Overview

##### 6.4.2 6.4.2 Market Analysis

##### 6.4.2 6.4.2 Market Analysis

## 6.5 MONOCLONAL ANTIBODY (MAB)

### 6.5.1 Overview

### 6.5.2 Market Analysis

## 6.6 INTERFERON (IFN)

### 6.6.1 6.6.1 Overview

### 6.6.2 Market Analysis

## 7. GLOBAL BIOSIMILARS MARKET ANALYSIS – DEVELOPED & EMERGING NATIONS

### 7.1 DEVELOPED MARKET

#### 7.1.1 Europe

#### 7.1.2 The US

### 7.2 EMERGING MARKET

#### 7.2.1 China

#### 7.2.2 India

## 8. GLOBAL BIOSIMILARS – PRICING ANALYSIS

## 9. GLOBAL BIOSIMILAR INDUSTRY – SWOT ANALYSIS

## 10. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS INDEX

## 11. GLOBAL BIOSIMILARS MARKET DYNAMICS

### 11.1 INDUSTRY TRENDS & DEVELOPMENTS

#### 11.1.1 New Biosimilars Dominated by Large Globals

#### 11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA

#### 11.1.3 11.1.3 Focus on Pharmerging Markets

### 11.2 GROWTH DRIVERS

#### 11.2.1 11.2.1 Biological Patent Expiries

#### 11.2.2 11.2.2 Cost saving

#### 11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases

### 11.3 CHALLENGES

#### 11.3.1 11.3.1 High Cost of Development

#### 11.3.2 11.3.2 Regulatory Uncertainty

#### 11.3.3 11.3.3 Lower Adoption Rate of Biosimilars

#### 11.3.4 11.3.4 Manufacturer Skills Gap

## **12. COMPETITIVE LANDSCAPE**

12.1 MARKET SHARE BY COMPETITORS

12.2 MARKET SHARE BY DRUGS

## **13. COMPANY PROFILES**

13.1 SANDOZ

13.2 HOSPIRA

13.3 TEVA

13.4 CELLTRION

13.5 BIOCAD

13.6 DONG-A PHARMACEUTICAL CO., LTD

13.7 STADA

## I would like to order

Product name: Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020

Product link: <https://marketpublishers.com/r/GDA5D9EABACEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDA5D9EABACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970